Personal Importation Policy (PIP)

Similar documents
FDA Basics FDA s Import Operations: How FDA Regulates Imported Products

TOBACCO PRODUCT OR MEDICAL PRODUCT?

TSDR Pharmacy Inc. dba brandmd Skin Care 11/9/17

RESEARCH INVOLVING PRISONERS

Mark M. Yacura. Partner

San Diego Compounding Pharmacy 9/25/17

Introduction. Current status of 510(k) clinical data requirements. 1 Current Status&Considerations:

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Talon Compounding Pharmacy 10/3/17

Town and Country Compounding and Consultation Services, LLC 10/17/17

DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Apini$r$iy -tq 5-f

Over the Counter Hearing Aids:

Border Issues and Statistics: Regulatory Activities. Mr. Robert Deininger Southwest Import Director AFDO San Antonio, Texas

Guidance - IDE Early/Expanded Access for Devices

New England Compounding Center 04-Dec-06

The Marketing of a Food Ingredient Understanding a System that has Worked for 105 Years

Distillers Grains Opportunities and Challenges

FDA REGULATION OF DIETARY SUPPLEMENTS AND FOODS

Is FDA s Spice Risk Profile Good News or Bad News for the Spice Industry?

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

The FDA Food Safety Modernization Act: The Key New Requirements

Commercial Feed Mill Verification Task Procedures

Final Rule for Preventive Controls for Animal Food

Safety Evaluation for Substances Directly Added to Food

BEST PRACTICE CHANGE CONTROL : DECIDING WHEN TO SUBMIT A 510(K) FOR A DEVICE CHANGE. Yuan Xu 18- JAN- 2018

Important Information about your 2.0 ml Animas Insulin Pump Cartridges

ARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH

Questions or comments regarding the content of the NHPD Monthly Communiqué may be addressed to

IMPAACT MOCHA More Options for Children and Adolescents

Section 7 ALARA Program

Amy Larrick Chavez-Valdez, Director, Medicare Drug Benefit and C & D Data Group

Stonegate Pharmacy LP 11/10/16

Inspections, Compliance, Enforcement, and Criminal Investigations. Central Texas Regional Blood & Tissue Center 07-Nov-03

CHAPTER Section 3 of P.L.1983, c.296 (C.45: ) is amended to read as follows:

Overview of the Legal Framework for Medical Device Regulation in the United States

GCC Guide for Control on Imported Foods

FDA Sampling Guidance and Practices. Terri McConnell FDA/ORA/Office of Regulatory Science

Compare Results. 153 Replacements 26 Insertions 344 Deletions. Total Changes. Styling and. Content. 0 Annotations. Old File: New File:

104 CMR: DEPARTMENT OF MENTAL HEALTH 104 CMR 33.00: DESIGNATION AND APPOINTMENT OF QUALIFIED MENTAL HEALTH PROFESSIONALS

AFDO Conference June 9, Mercedes Mota, Director Medical Device, Surgical Care Johnson & Johnson Quality & Compliance Worldwide

Alignment of FSMA with Existing Food Safety Programs International Citrus & Beverage Conference

WYOMING CHILDHOOD IMMUNIZATION RULES CHAPTER 7 COVERED SERVICES

Getting Your Ingredient to Market: Understanding Your Regulatory Options Venable LLP

Changing the Drug Enforcement Administration (DEA) Schedule of Tetrahydrocannabinol (THC), Cannabidiol and Combinations to Promote Research

Hieber's Pharmacy 12/5/17

Gyan Rai, PhD 06/04/2015

FDA Food Safety Modernization Act (FSMA) January 4, 2011

CENTER FOR DRUG EVALUATION AND RESEARCH. APPLICATION NUMBER: Orig1s000 APPROVAL LETTER

American Emu Association. Certified Emu Oil Program

NDA NDA APPROVAL

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

OVERVIEW OF THE 2017 VFD PROGRAM

720 cases. 20 states. Conflict of Interest Declaration. New England Compounding Center (NECC) timeline. (NECC) timeline (continued) 3/28/2013

OKLAHOMA STATE UNIVERSITY X-RAY MACHINE PROGRAM AND PI HANDBOOK For easy navigation, please use Adobe s bookmark feature.

Maryland Vaccines for Children Program VACCINE MANAGEMENT PLAN

Southern California Section & Western Compendial Discussion Group

Quality. Guaranteeing High Quality. Outsourced Pharmacy Services. Disclosure 3/18/2013

Chapter 18 Section 2. EXPIRED - Department Of Defense (DoD) Cancer Prevention And Treatment Clinical Trials Demonstration

HEARING CONSERVATION PROGRAM

Responding to a Food Recall

Impact Summary: Therapeutic Products Bill Personal Import of Medicine by mail/courier

Medical Device Approval and Product Recalls

INTRODUCTION TO DRUG LAW AND REGULATION: REGULATION OF DRUG MANUFACTURING

Disclosure. Objectives. Objectives. Introduction. Introduction. Non-Sterile Compounding/Calculations

Information about cases being considered by the Case Examiners

Mini Summit XIV: Clinical Trial Disclosure and Results Reporting Liability under FDAAA, Section 801

DETERMINING WHETHER AN ACTIVITY IS HUMAN SUBJECTS RESEARCH AS DEFINED BY FEDERAL REGULATIONS

4/26/2013. Libia Lugo Drug Specialist San Juan District Office Investigations Branch

6/7/2017 CHANGES IN PHARMA REGULATIONS HOW IT AFFECTS THE OR NURSE DISCLOSURE OBJECTIVES

GEX Recommended Procedure Eff. Date: 07/27/07 Rev.: C Pg. 1 of 10

METROLINX ADMINISTRATIVE FEE DISPUTE RESOLUTION PROCESS RULES OF PRACTICE

NOTICE OF INITIATION OF DISQUALIFICATION PROCEEDINGS AND OPPORTUNITY TO EXPLAIN

OHRP Guidance on the Involvement of Prisoners in Research

FDA Oversight of Nanotechnology Applications in Foods, Food Packaging, and Nutrient Delivery

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

Inspections, Compliance, Enforcement, and Criminal Investigations

Canadian Grain Commission

The Food and Drug Administration Globalization Act of 2008

Allergy Inspection Guide (4/01)

DRDO.MM 32 Page No. 1/3 CDE Certificate No. : Date :

Naloxone Expanded Access: OTC status Considerations for a Nonprescription Drug Development Program

Scientific Working Group on Digital Evidence

See Important Reminder at the end of this policy for important regulatory and legal information.

Compounding Pharmacy Pharmacy s Past, Present & Future

Medicare Part D Overutilization Monitoring System

CERTIFIED MAIL RETURN RECEIPT REQUESTED. Esther Hernandez President United States Blood Bank, Inc NW 95th Avenue Miami, Florida

Guide to Interchangeable Medicines

The Who? What? Where? And Why? That the Regulatory Board Member Needs to Know About Foreign-Educated Physical Therapists

The Tobacco Control Act s Premarket Review Authorities: Reports on Substantial Equivalence and Exemption Requests (905(j))

Foreign Supplier Verification Programs for Importers of Food for Humans and Animals

Peramivir IV Questions and Answers for Health Care Providers

HUMAN RESEARCH PROTECTIONS - PRISONERS

FDA Food Contact Fundamentals

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF NEW MEXICO ) ) ) ) ) ) ) ) ) INFORMATION. General Allegations. A. Introduction and Background

Application for Accreditation of Training Program in Renal Ultrasonography

LIVE INTERACTIVE YOUR DESKTOP. Food Recall Process. Cecilia M. Wolyniak Food and Drug Administration Office of Enforcement

Administration of Medication

Background. Introduction

Medical Devices and the Public s Health: The FDA 510(k) Clearance Process at 35 Years. Written Statement of

The Path to U.S. Market for Functional Food Ingredients

Transcription:

Personal Importation Policy (PIP) CDR Paras Patel, R.Ph., MBA US Food & Drug Administration Center for Drug Evaluation and Research Drug Shortage Staff

Objectives Describe the purpose of the Personal Importation Policy (PIP) Provide qualifications of drugs and devices that may be eligible for importation Identify labelling recommendations Review potential documents that patients can encounter during importation

Personal Importation Policy: Purpose To allow import of unapproved drugs or devices in small quantities, for personal use or to continue treatment with a drug from a foreign country, that are not available in the USA Factors the FDA considers: -drug is unapproved and/or not available in the USA -drug is for serious medical illness, where there is no domestically available treatment -drug should not indicate a health risk that is unreasonable (safety of the patient is considered) -request must have affirmation of drug use, patient s and physician s information Policy protects patients from legal persecution on a case by case basis

Potential Pathway Patient/practitioner request for an unapproved product to get into the US. Patient has rare illness Patient finds treatment in a foreign country, not available in the US Product is shipped and detained at US border by Customs and Border Protection (CBP) Proper documents may be reviewed by FDA for consideration Release without detainment Detainment and hearing

Key points to consider for personal drug importation 1. Identify a safe source of the drug or device 2. Scale of import- 3 months supply 3. Notify the international source of labelling requirements 4. Physician supervision- letter explaining intent for drug use and other required information 5. Letter may be sent from the FDA if the package is detained at the border

What kind of drugs or devices can be imported? PIP allows patients to access unapproved drugs available in other countries for the following reasons: -Serious medical illnesses -Treatment is not available in the USA -Illnesses that began in another country-where therapy was started -No serious health risk to the patient Unapproved drugs that violate(import alert) FDCA cannot be imported Regulatory Procedures Manual - April 2013 Chapter 9 Import Operations and Actions. http://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproceduresmanual/ucm074300.pdf. Pg 9.11-9.14.

Can I get drugs from another country if they re less expensive? No. PIP does not allow importing FDA approved drugs that are cheaper in other foreign countries FDA cannot confirm the approved products made foreign are: properly manufactured safe and effective same formulations as in the FDA approved products Through discretion, PIP considers: unapproved drugs, with no equivalent treatment in the US, used for the treatment of severe medical conditions continuation of foreign begun treatment with an unapproved drug

How much drug can be imported at once? 3 months supply or less. Larger quantities will be returned to the sender or discarded if deemed unsafe.

Is a prescription required? No. However, a letter from a physician may be requested, for an appropriate decision, stating: 1. Name of licensed physician 2. Address of United States licensed physician, who is taking responsibility for the patient and the drug therapy 3. Signature and consent that the physician will supervise the use of the drug or device, which will only be used for patient (not for distribution) 4. Intended use of the drug

How should one label the product? Make sure the product is properly labelled: drug/device name/description on the product itself or piece of paper with drug information plus identification on the packaging that the contents is a drug *without proper labelling, a sample may need to be taken and sent to a lab which will delay receipt, possibly contaminate the product and remove drug that could be used on the patient

Can a patient notify the FDA before shipping the product to assure successful importation? No such requirements or procedures to recevice such a notification. Provide all required documentation/justification with the product that is to be shipped into the United States. Wait for a letter from the FDA when it arrives at the domestic port of entry.

Are forms required to import a drug? There are no forms to allow an unapproved drug for importation The Personal Importation Policy is used as a guidance by the FDA for enforcement discretion in certain situations Requests are analyzed individually, on a case-by-case basis Regulatory Procedures Manual - April 2013 Chapter 9 Import Operations and Actions. http://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproceduresmanual/ucm074300.pdf. Pg 9.11-9.14.

What forms could I receive from the FDA? A Notification of Detention and Hearing will be sent for unapproved drug products: This drug is not approved by the FDA. To release this product please provide: i. Documentation that product is for personal use, and for treatment of a serious condition ii. Include name and address of licensed physician who is responsible for your treatment using this product iii. Adequate documentation that the product is continuing treatment for a serious disease begun in a foreign country Regulatory Procedures Manual - April 2013 Chapter 9 Import Operations and Actions. http://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproceduresmanual/ucm074300.pdf. Pg 9-84.

Release with Comment Form When a shipment is NOT denied entry: a. The drug or device is for personal use, and is unapproved in the USA b. The drug must be used under medical supervision c. FDA may detain future shipments of this product d. The patient s physician should consider enrolling the patient in an investigational study or applying for an appropriate Investigational New Drug (IND), compassionate IND, or Treatment IND exemption. Regulatory Procedures Manual - April 2013 Chapter 9 Import Operations and Actions. http://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryproceduresmanual/ucm074300.pdf. Pg 9-84.

If a patient follows these guidelines, will he or she be guaranteed to receive the imported drug or device? No. These are guidelines to provide clarity on the intent of the PIP policy. Each use of the PIP will be examined on a case to case basis.

Thank You for Your Time! FDA Homepage: http://www.fda.gov/ Personal Importation: http://www.fda.gov/forindustry/importprogram/importbasics/ucm432661.htm#co ntrolled Regulatory Procedures Manual: http://www.fda.gov/downloads/iceci/compliancemanuals/regulatoryprocedures Manual/UCM074300.pdf